DMTK - DermTech Inc Stock Price, Fair Value and News

0.52USD-0.05 (-8.77%)Delayed as of 17 May 2024, 01:09 pm ET

Market Summary

USD0.52-0.05

Delayedas of 17 May 2024, 01:09 pm

-8.77%

DMTK Stock Price

View Fullscreen

DMTK RSI Chart

DMTK Valuation

Market Cap

19.9M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

1.27

Price/Free Cashflow

-0.28

DMTK Price/Sales (Trailing)

DMTK Profitability

Operating Margin

8.51%

Return on Equity

-224.08%

Return on Assets

-87.03%

Free Cashflow Yield

-362.36%

DMTK Fundamentals

DMTK Revenue

Revenue (TTM)

15.7M

Rev. Growth (Yr)

10.58%

Rev. Growth (Qtr)

-2.01%

DMTK Earnings

Earnings (TTM)

-89.6M

Earnings Growth (Yr)

36.04%

Earnings Growth (Qtr)

-4.76%

Breaking Down DMTK Revenue

52 Week Range

0.523.90

(Low)(High)

Last 7 days

-8.1%

Last 30 days

-6.6%

Last 90 days

-57.1%

Trailing 12 Months

-77.7%

How does DMTK drawdown profile look like?

DMTK Financial Health

Current Ratio

3.53

DMTK Investor Care

Shares Dilution (1Y)

12.46%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	15.7M	0	0	0
2023	14.3M	14.0M	14.4M	15.3M
2022	13.0M	14.1M	14.7M	14.5M
2021	6.9M	9.1M	10.8M	11.8M
2020	4.3M	4.6M	5.4M	5.9M
2019	2.5M	2.5M	2.4M	3.4M
2018	1.2M	1.6M	2.0M	2.4M
2017	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of DermTech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 10, 2024	sun kevin m	sold (taxes)	-311	0.7	-445	chief financial officer
Mar 05, 2024	akhavan ramin	sold (taxes)	-3,297	0.88	-3,747	general counsel
Mar 05, 2024	sun kevin m	sold (taxes)	-4,354	0.88	-4,948	chief financial officer
Jan 05, 2024	akhavan ramin	sold (taxes)	-4,803	1.5	-3,202	general counsel
Dec 11, 2023	sun kevin m	sold	-648	1.45	-447	chief financial officer
Dec 11, 2023	ibarra claudia	sold	-479	1.45	-331	chief operating officer
Dec 08, 2023	ibarra claudia	sold	-3,675	1.41	-2,607	chief operating officer
Dec 07, 2023	akhavan ramin	sold	-5,765	1.53	-3,768	general counsel
Dec 07, 2023	ibarra claudia	sold	-5,983	1.53	-3,911	chief operating officer
Dec 07, 2023	sun kevin m	sold	-7,617	1.53	-4,979	chief financial officer

Which funds bought or sold DMTK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Engineers Gate Manager LP	sold off	-100	-22,061	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-59.77	-41,490	7,984	-%
May 15, 2024	ORACLE INVESTMENT MANAGEMENT INC	unchanged	-	-49,976	33,476	0.02%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-93,434	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-275,460	-	-%
May 15, 2024	MARSHALL WACE, LLP	unchanged	-	-60,456	40,304	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	54.36	-9,647	15,688	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	27.00	27.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-54.05	-8,087	1,827	-%
May 15, 2024	Royal Bank of Canada	added	11.71	-1,000	-	-%

Are Funds Buying or Selling DMTK?

Are funds buying DMTK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DMTK

No. of Funds

Unveiling DermTech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 26, 2024	van herk investments b.v.	5.1%	1,778,057	SC 13G
Feb 08, 2024	van herk investments b.v.	4.8%	1,628,057	SC 13G/A
Dec 12, 2023	rtw investments, lp	0%	0	SC 13D/A
Jun 16, 2023	van herk investments b.v.	5.0%	1,559,931	SC 13G/A
Feb 14, 2023	casdin capital, llc	0%	0	SC 13G/A
Feb 03, 2023	state street corp	0.45%	137,349	SC 13G/A
Nov 08, 2022	rtw investments, lp	9.99%	3,018,666	SC 13D/A
Jul 11, 2022	state street corp	0.57%	170,866	SC 13G/A
Jul 08, 2022	blackrock inc.	1.6%	484,692	SC 13G
Feb 14, 2022	casdin capital, llc	5.87%	1,745,000	SC 13G/A

Recent SEC filings of DermTech Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 10, 2024	8-K	Current Report
Apr 26, 2024	SC 13G	Major Ownership Report
Apr 26, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Mar 12, 2024	4/A	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 07, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to DermTech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.1B	23.7B	10.13%	17.51%	44.54	8.26	-8.94%	-35.91%
A	45.2B	6.7B	12.76%	20.73%	36.58	6.71	-2.81%	-6.58%
IDXX	44.7B	3.7B	10.56%	11.11%	51.58	12	8.57%	23.94%
DGX	15.8B	9.3B	11.84%	7.84%	18.71	1.7	-3.29%	6.68%
NTRA	13.3B	1.2B	20.21%	118.71%	-36.48	11.03	39.26%	33.08%
MEDP	12.2B	2.0B	2.04%	87.82%	38.96	6.2	25.57%	21.62%
CRL	11.6B	4.1B	-3.32%	14.15%	26.37	2.81	0.49%	-11.59%
EXAS	9.6B	2.5B	-18.63%	-33.92%	-39.91	3.78	15.21%	53.51%
MID-CAP
GH	3.2B	603.7M	62.38%	-9.67%	-6.97	5.32	25.21%	30.68%
NEOG	2.9B	929.2M	10.28%	-20.84%	1.9K	3.13	28.93%	111.61%
SMALL-CAP
CDNA	769.8M	275.1M	88.15%	90.09%	-4.2	2.8	-13.93%	-126.97%
ACRS	84.1M	31.1M	-4.10%	-85.92%	-1.09	2.7	0.95%	19.75%
AWH	32.9M	9.2M	-21.45%	-32.59%	-2.23	3.59	11.85%	45.80%
APDN	2.7M	5.5M	708.82%	139.13%	-0.22	0.49	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

DermTech Inc News

Latest updates

DermTech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.0%	3,845	3,924	3,915	3,980	3,477	2,994	3,573	4,233	3,718	3,165	3,030	3,119	2,524	2,122	1,362	844	1,557	1,589	565	614	596
Cost Of Revenue	-10.1%	3,132	3,484	3,743	3,972	3,821	3,350	3,694	3,273	3,554	3,040	2,898	2,624	2,002	1,725	1,608	1,445	1,203	1,204	779	686	635
Gross Profit	62.0%	713	440	172	8.00	-344	-356	-121	960	164	125	132	495	522	397	-246	-601	354	385	-214	-72.00	-39.00
Operating Expenses	5.1%	21,221	20,192	19,982	32,140	31,701	28,523	29,140	30,794	30,355	26,484	20,451	17,802	13,935	9,861	9,151	8,826	7,355	5,500	5,945	3,256	2,964
S&GA Expenses	-7.2%	7,817	8,422	8,123	13,033	15,417	13,598	14,632	15,001	15,443	13,330	9,826	7,907	6,512	5,105	4,594	3,433	2,944	2,431	1,976	1,032	864
R&D Expenses	-2.4%	3,266	3,348	3,595	3,887	4,409	5,097	5,702	6,915	6,338	5,990	4,426	3,594	2,251	1,914	1,618	864	897	650	757	518	572
Interest Expenses	400.0%	5.00	1.00	2.00	1.00	1.00	3.00	3.00	4.00	3.00	4.00	5.00	4.00	4.00	-	-	-	-	-	-	-	-
Net Income	-4.8%	-20,000	-19,091	-19,164	-31,363	-31,270	-28,223	-28,772	-29,580	-30,108	-26,053	-20,112	-17,102	-15,068	-10,702	-9,281	-9,597	-6,897	-5,556	-5,726	-3,692	-5,156
Net Income Margin	13.3%	-5.72*	-6.60*	-7.66*	-8.53*	-8.25*	-8.04*	-7.80*	-7.48*	-7.17*	-6.62*	-5.83*	-5.71*	-	-	-	-	-	-	-	-	-
Free Cashflow	-36.5%	-17,119	-12,544	-19,092	-23,460	-22,785	-23,163	-24,813	-25,120	-25,469	-23,736	-16,619	-13,743	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-15.5%	103	122	138	157	177	202	194	216	240	248	270	276	265	70.00	57.00	65.00	72.00	18.00	24.00	12.00	12.00
Current Assets	-28.4%	44.00	62.00	76.00	94.00	112	136	161	184	208	233	254	272	262	67.00	55.00	62.00	70.00	17.00	24.00	0.00	0.00
Cash Equivalents	-24.9%	28.00	37.00	37.00	43.00	48.00	78.00	95.00	120	145	177	204	230	219	24.00	15.00	61.00	68.00	15.00	21.00	0.00	0.00
Inventory	-17.2%	1.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Net PPE	-9.8%	4.00	5.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	0.00	-	-
Liabilities	-2.7%	63.00	65.00	65.00	69.00	70.00	70.00	39.00	38.00	36.00	19.00	18.00	8.00	8.00	8.00	5.00	6.00	6.00	6.00	5.00	7.00	7.00
Current Liabilities	-6.9%	13.00	13.00	13.00	16.00	16.00	16.00	17.00	15.00	14.00	12.00	11.00	8.00	7.00	5.00	4.00	-	-	6.00	5.00	2.00	2.00
Shareholder's Equity	-30.0%	40.00	57.00	73.00	88.00	107	132	155	179	203	230	252	267	257	62.00	52.00	58.00	66.00	12.00	19.00	5.00	5.00
Retained Earnings	-4.7%	-443	-423	-404	-385	-354	-323	-294	-266	-236	-206	-180	-160	-143	-128	-117	-108	-98.45	-91.55	-86.00	2.00	2.00
Additional Paid-In Capital	0.6%	484	481	478	474	462	456	451	445	441	436	432	428	400	190	169	166	165	103	105	-	-
Shares Outstanding	1.3%	35.00	35.00	34.00	33.00	31.00	30.00	30.00	30.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	85.00	-	-	-	147	-	-	-	978	-	-	-	151	-	-	-	6.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-34.7%	-17,119	-12,707	-19,043	-23,201	-22,028	-21,230	-24,801	-24,406	-24,823	-22,680	-15,899	-12,811	-10,716	-6,747	-8,157	-6,383	-7,397	-6,080	-7,715	-25.70	-2,706
Share Based Compensation	-14.4%	2,697	3,151	3,163	7,515	4,736	5,267	4,936	4,837	3,894	3,830	3,736	3,538	2,172	1,449	1,373	1,125	1,022	104	685	257	258
Cashflow From Investing	-36.0%	7,834	12,243	12,757	13,058	-8,194	3,539	-466	141	-7,533	-4,523	-7,596	-178	-215	-2,857	-37,282	-1,026	-175	-157	-41.00	-6.00	-6.00
Cashflow From Financing	608.3%	122	-24.00	726	4,461	916	-33.00	433	-10.00	527	25.00	971	24,003	205,278	19,227	-1,038	589	60,120	174	25,807	11.00	-136,914

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DMTK Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 3,845	$ 3,477
Cost of revenues:
Total cost of revenues	3,132	3,821
Gross profit/(loss)	713	(344)
Operating expenses:
Sales and marketing	7,817	15,417
Research and development	3,266	4,409
General and administrative	10,138	11,875
Total operating expenses	21,221	31,701
Loss from operations	(20,508)	(32,045)
Nonoperating Income (Expense) [Abstract]
Interest income, net	498	782
Change in fair value of warrant liability	0	(7)
Total other income	498	775
Net loss	$ (20,010)	$ (31,270)
Weighted average shares outstanding used in computing net loss per share, basic (in shares)	34,706,491	30,557,216
Weighted average shares outstanding used in computing net loss per share, diluted (in shares)	34,706,491	30,557,216
Net loss per share of common stock outstanding, basic (in usd per share)	$ (0.58)	$ (1.02)
Net loss per share of common stock outstanding, diluted (in usd per share)	$ (0.58)	$ (1.02)
Test revenue
Revenues:
Total revenues	$ 3,677	$ 3,425
Cost of revenues:
Total cost of revenues	3,085	3,791
Contract revenue
Revenues:
Total revenues	168	52
Cost of revenues:
Total cost of revenues	$ 47	$ 30

DMTK Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 27,579	$ 36,741
Short-term marketable securities	11,400	19,123
Accounts receivable	2,497	2,584
Inventory	831	1,004
Prepaid expenses and other current assets	1,892	2,300
Total current assets	44,199	61,752
Property and equipment, net	4,498	4,988
Operating lease right-of-use assets	50,806	51,722
Restricted cash	3,467	3,468
Total assets	102,970	121,930
Current liabilities:
Accounts payable	1,913	1,484
Accrued compensation	5,248	6,664
Accrued liabilities	1,943	2,017
Short-term deferred revenue	203	196
Current portion of operating lease liabilities	3,194	3,069
Current portion of finance lease obligations	17	17
Total current liabilities	12,518	13,447
Long-term finance lease obligations, less current portion	34	38
Operating lease liabilities, long-term	50,424	51,270
Total liabilities	62,976	64,755
Stockholders’ equity:
Common stock, $0.0001 par value per share; 100,000,000 and 100,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 34,962,994 and 34,524,677 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	3	3
Additional paid-in capital	483,752	480,929
Accumulated other comprehensive income	184	178
Accumulated deficit	(443,945)	(423,935)
Total stockholders’ equity	39,994	57,175
Total liabilities and stockholders’ equity	$ 102,970	$ 121,930

About DermTech Inc

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

CEO	Mr. Bret Christensen
WEBSITE	dermtech.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	278

DermTech Inc Frequently Asked Questions

What is the ticker symbol for DermTech Inc? What does DMTK stand for in stocks?

DMTK is the stock ticker symbol of DermTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DermTech Inc (DMTK)?

As of Thu May 16 2024, market cap of DermTech Inc is 19.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DMTK stock?

You can check DMTK's fair value in chart for subscribers.

What is the fair value of DMTK stock?

You can check DMTK's fair value in chart for subscribers. The fair value of DermTech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DermTech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DMTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DermTech Inc a good stock to buy?

The fair value guage provides a quick view whether DMTK is over valued or under valued. Whether DermTech Inc is cheap or expensive depends on the assumptions which impact DermTech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DMTK.

What is DermTech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, DMTK's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 1.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DMTK PE ratio will change depending on the future growth rate expectations of investors.